Methods for gene delivery to neural tissue

Methods in Genomic Neuroscience

Volumn , Issue , 2001, Pages 229-266

  Hampl, Jürgen A ^a   Brown, Alice B ^a   Rainov, Nikolai G ^b   Breakefield, Xandra O ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746464792     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (268)

1. Rainov, N. G., A phase III clinical evaluation of Herpes Simplex Virus Type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme, Hum. Gene Ther., 20, 2389, 2000.
2. Muldoon, L. L. et al., Delivery of therapeutic agents to brain and intracerebral tumors, in Gene Therapy for Neurologic Disorders and Brain Tumors, Chiocca, E. A. and Breakefield, X. O., Eds., Humana Press, Totowa, NJ, 1998, 295.
3. Gage, F. H. and Fisher, L. J., Intracerebral grafting: A tool for the neurobiologist, Neuron, 6, 1, 1991.
4. Short, M. P. et al., Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line, J. Neurosci. Res., 27, 427, 1990.
5. Miller, D. G., Adam, M. A., and Miller, A. D., Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection, Mol. Cell Biol., 10, 4239, 1990.
6. Hampl, J. A. et al., Transduction of glioma cells into retrovirus vector producers with herpes simplex virus-Epstein Barr virus hybrid amplicon vectors in culture and in tumors, in preparation.
7. Martuza, R. L. et al., Experimental therapy of human glioma by means of a genetically engineered virus mutant, Science, 252, 854, 1991.
8. Goldsmith, K. T. et al., Trans complementation of an E1A-deleted adenovirus with codelivered E1A sequences to make recombinant adenoviral producer cells, Hum. Gene Ther., 5, 1341, 1994.
9. Boviatsis, E. J. et al., Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase, Gene Ther., 1, 323, 1994.
10. Gage, F. H., Stem cells of the central nervous system, Curr. Opin. Neurobiol., 8, 671, 1998.
11. Aboody, K. S. et al., Foreign-gene-expressing mouse and human neural stem cells display extensive tropism for adult intracranial gliomas, Proc. Natl. Acad. Sci. USA, 97, 12846, 2000.
12. Herrlinger, U. et al., Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas, Mol. Ther., 1, 347, 2000.
13. Lal, B. et al., Endothelial cell implantation and survival within experimental gliomas, Proc. Natl. Acad. Sci. USA, 91, 9695, 1994.
14. Uteza, Y. et al., Intravitreous transplantation of encapsulated fibroblasts secreting the human fibroblast growth factor 2 delays photoreceptor cell degeneration, in Royal College of Surgeons rats, Proc. Natl. Acad. Sci. USA, 96, 3126, 1999.
15. Kramm, C. M. et al., Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment, Hum. Gene Ther., 7, 1989, 1996.
16. Snyder, E. Y., Taylor, R. M., and Wolfe, J. H., Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain, Nature, 374, 367, 1995.
17. Muldoon, L. L. et al., Comparison of intracerebral inoculation and osmotic bloodbrain barrier disruption for delivery of adenovirus, herpesvirus and iron oxide nanoparticles to normal rat brain, Am. J. Pathol., 147, 1840, 1995.
18. Nilaver, G. et al., Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption, Proc. Natl. Acad. Sci. USA, 92, 9829, 1995.
19. Rainov, N. G. et al., Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms, Hum. Gene Ther., 6, 1543, 1995.
20. Rainov, N. G. et al., Long term survival in a rodent brain tumor model by bradykininenhanced intra-arterial delivery of a therapeutic herpes-simplex virus vector, Cancer Gene Ther., 5, 158, 1998.
21. Barnett, F. H. et al., Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7, Cancer Gene Ther., 6, 14, 1999.
22. Inamura, T. and Black, K. L., Bradykinin selectively opens blood-tumor barrier in experimental brain tumors, J. Cereb. Blood Flow Metab., 14, 862, 1994.
23. Miller, C. R. et al., Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer, Cancer Res., 58, 5738, 1998.
24. Jin, B. K. et al., Prolonged in vivo gene expression driven by a tyrosine hydroxylase promoter in a defective herpes simplex virus amplicon vector, Hum. Gene Ther., 7, 2015, 1996.
25. Brenner, M. et al., GFAP promoter directs astrocyte-specific expression in transgenic mice, J. Neurosci., 14, 1030, 1994.
26. Martuza, R., personal communication.
27. Kramm, C. M. et al., Gene therapy for brain tumors, Brain Pathol., 5, 345, 1995.
28. Zurn, A. D., Tseng, J., and Aebischer, P., Treatment of Parkinson’s disease. Symptomatic cell therapies: Cells as biological minipumps, Eur. Neurol., 36, 405, 1996.
29. Tuszynski, M. H. et al., Grafts of genetically modified Schwann cells to the spinal cord: Survival, axon growth, and myelination, Cell Transplant, 7, 187, 1998.
30. Markert, J. M. et al., Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial, Gene Ther., 7, 867, 2000.
31. Sandmair, A. M., Vapalahi, M., and Yla-Herttuala, S., Adenovirus-mediated herpes simplex thymidine kinase gene therapy for brain tumors, Adv. Exp. Med. Biol., 465, 163, 2000.
32. Brooks, A. I. et al., Reproducible and efficient murine CNS gene delivery using a microprocessor-controlled injector, J. Neurosci. Meth., 80, 137, 1998.
33. Hagihara, Y. et al., Widespread gene transfection into the central nervous system of primates, Gene Ther., 7, 759, 2000.
34. Jiao, S., Gurevich, W., and Wolff, J. A., Long-term correction of rat model of Parkinson’s disease by gene therapy, Nature, 3621, 450, 1993.
35. Sato, H. et al., In vivo gene gun-mediated DNA delivery into rodent brain tissue, Biochem. Biophys. Res. Comun., 270, 163, 2000.
36. Wagner, E. et al., Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes, Proc. Natl. Acad. Sci. USA, 89, 6099, 1992.
37. Saeki, Y. et al., Development and characterization of cationic liposomes conjugated with HSJ (Sendai virus): Reciprocal effect of cationic lipid for in vitro and in vivo gene transfer, Hum. Gene Ther., 8, 2133, 1997.
38. Aronsohn, A. I. and Hughes, J. A., Nuclear localization signal peptides enhance cationic liposome-mediated gene therapy, J. Drug Target, 5, 163, 1998.
39. Namiki, Y., Takahashi, T., and Ohno, T., Gene transduction for disseminated intraperitoneal tumor using cationic liposomes containing non-histone chromatin proteins:Cationic liposomal gene therapy of carcinomatosa, Gene Ther., 5, 240, 1998.
40. Bearer, E. L. et al., Retrograde axonal transport of herpes simplex virus: Evidence for a single mechanism and a role for tegument, Proc. Natl. Acad. Sci. USA, 97, 8146, 2000.
41. Sodeik, B., Ebersold, M. W., and Helenius, A., Microtubule-mediated transport of incoming herpes simplex virus 1 capsids to the nucleus, J. Cell Biol., 136, 1007, 1997.
42. Nemerow, G. R. and Stewart, P. L., Role of alpha(v) integrins in adenovirus cell entry and gene delivery, Microbiol. Mol. Biol. Rev., 63, 725, 1999.
43. Breakefield, X. O. and DeLuca, N. A., Herpes simplex virus for gene delivery to neurons, New Biol., 3, 203, 1991.
44. Benihoud, K. et al., The role of IL-6 in the inflammatory and humoral response to adenoviral vectors, J. Gene Med., 2, 104, 2000.
45. Wu, N. et al., Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22, J. Virol., 70, 6358, 1996.
46. Krisky, D. M. et al., Deletion of multiple immediate early genes from herpes simplex virus reduces cytotoxicity and improves gene transfer to neurons in culture, Gene Ther., 5, 1593, 1998.
47. Palmer, J. A. et al., Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system, J. Virol., 74, 5604, 2000.
48. Ginsberg, H. S. and Prince, G. A., The molecular basis of adenovirus pathogenesis, Infect. Agents Dis., 3, 1, 1994.
49. Millhouse, S. and Wigdahl, B., Molecular circuitry regulating herpes simplex virus type 1 latency in neurons, J. Neurovirol., 6, 6, 2000.
50. Coffin, R. S. et al., The herpes simplex virus 2 kb latency associated transcript (LAT) leader sequence allows efficient expression of downstream proteins which is enhanced in neuronal cells: Possible function of LAT ORFs, J. Gen. Virol., 79, 3019, 1998.
51. Soares, K. et al., cis-Acting elements involved in transcriptional regulation of the herpes simplex virus type 1 latency-associated promoter 1 (LAP1) in vitro and in vivo, J. Virol., 70, 5384, 1996.
52. Yates, J. L., Warren, N., and Sugden, B., Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells, Nature, 313, 812, 1985.
53. Wang, S. and Vos, J.-M., A hybrid herpes virus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo, J. Virol., 70, 8422, 1996.
54. Peel, A. L. and Klein, R. L., Adeno-associated virus vectors: Activity and applications in the CNS, J. Neurosci. Methods, 98, 95, 2000.
55. Hamlin, J. L., Mammalian origins of replication, Bioessays, 14, 651, 1992.
56. Grimes, B. and Cooke, H., Engineering mammalian chromosomes, Hum. Mol. Genet., 7, 1635, 1998.
57. Shelling, A. N. and Smith, M. G., Targeted integration of transfected and infected adeno-associated virus vectors containing the neomycin-resistance gene, Gene Ther., 2, 1, 1994.
58. Balague, C., Kalla, M., and Zhang, W. W., Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome, J. Virol., 71, 3299, 1997.
59. Thyagarajan, B. et al., Mammalian genomes contain active recombinase recognition sites, Gene, 244, 47, 2000.
60. Zhang, L. et al., The Himar1 mariner transposase cloned in a recombinant adenovirus vector is functional in mammalian cells, Nucl. Acids Res., 26, 3687, 1998.
61. Kotin, R. M., Linden, R. M., and Berns, K. I., Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by nonhomologous recombination, EMBO J., 11, 5071, 1992.
62. Jones, P. L. et al., Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription, Nat. Genet., 19, 187, 1998.
63. Rivella, S. et al., The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites, J. Virol., 74, 4679, 2000.
64. Kalos, M. and Fournier, R. E., Position-independent transgene expression mediated by boundary elements from the apolipoprotein B chromatin domain, Mol. Cell Biol., 15, 198, 1995.
65. Brisson, M. et al., Subcellular trafficking of the cytoplasmic expression system, Hum. Gene Ther., 10, 2601, 1999.
66. Isacson, O. and Breakefield, X. O., Benefits and risks of hosting animal cells in the human brain, Nat. Med., 3, 964, 1997.
67. Hottinger, A. F. and Aebischer, P., Treatment of diseases of the central nervous system using encapsulated cells, Adv. Tech. Stand. Neurosurg., 25, 3, 1999.
68. Ioannou, Y. A., Bishop, D. F., and Desnick, R. F., Overexpression of human alphagalactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion, J. Cell. Biol., 119, 1137, 1992.
69. Nam, M. et al., Endothelial cell-based cytokine gene delivery inhibits 9L glioma growth in vivo, Brain Res., 731, 161, 1996.
70. Jinnah, H. A. and Friedmann, T., Gene therapy and the brain, Br. Med. Bull, 51, 138, 1995.
71. Mandel, R. J. et al., Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson’s disease, J. Neurosci., 18, 4271, 1998.
72. Weidner, N. et al., Nerve growth factor-hypersecreting Schwann ell grafts augment and guide spinal cord axonal growth and remyelinate central nervous system axons in a phenotypically appropriate manner that correlates with expression of L1, J. Comp. Neurol., 413, 495, 1999.
73. Ohashi, T. et al., Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector, Proc. Natl. Acad. Sci USA, 89, 11332, 1992.
74. Hoogerbrugge, P. M. et al., Donor-derived cells in the central nervous system of twitcher mice after bone marrow transplantation, Science, 239, 1035, 1988.
75. Wolff, J. A. et al., Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease, Proc. Natl. Acad. Sci. USA, 86, 9011, 1989.
76. Quinonero, J. et al., Gene transfer to the central nervous system by transplantation of cerebral endothelial cells, Gene Ther., 4, 111, 1997.
77. Guenard, V. et al., Syngeneic Schwann cells derived from adult nerves seeded in semi-permeable guidance channels enhance peripheral nerve regeneration, J. Neurosci., 12, 3310, 1992.
78. Gussoni, E. et al., Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation, Nature, 356, 435, 1992.
79. Cunningham, L. et al., Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rat model of Parkinson disease, Brain Res., 658, 219, 1994.
80. Lachapelle, F. et al., Transplanted transgenically marked oligodendrocytes survive, migrate and myelinate in the normal mouse brain as they do in the shiverer mouse brain, Eur. J. Neurosci., 6, 814, 1994.
81. Bjorklund, A., Dopaminergic transplants in experimental Parkinsonism: Cellular mechanisms of graft-induced functional recovery, Curr. Opin. Neurobiol., 2, 683, 1992.
82. Decosterd, I. et al., Intrathecal implants of bovine chromaffin cells alleviate mechanical allodynia in a rat model of neuropathic pain, Pain, 76, 159, 1998.
83. Martinez-Serrano, A. and Bjorklund, A., Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modifed neural stem cells, J. Neurosci., 16, 4604-4646, 1996.
84. Trotter, J. et al., Lines of glial precursor cells immortalized with a temperaturesensitive oncogene give rise to astrocytes and oligodendrocytes following transplantation into demyelinated lesions in the central nervous system, Glia, 9, 25, 1993.
85. Rosenberg, M. B. et al., Grafting genetically modified cells to the damaged brain:Restorative effects of NGF expression, Science, 242, 1575, 1988.
86. Thorin, E. and Shreeve, S. M., Heterogeneity of vascular endothelial cells in normal and disease states, Pharmacol. Ther., 78, 155, 1998.
87. Yao, S. N. et al., Expression of human factor IX in rat capillary endothelial cells:Toward somatic gene therapy for hemophilia B, Proc. Natl. Acad. Sci. USA, 88, 8101, 1991.
88. Dichek, D. A. et al., Seeding of intravascular stents with genetically engineered endothelial cells, Circulation, 80, 1347, 1989.
89. Zwiebel, J. A. et al., High-level recombinant gene expression in rabbit endothelial cells transduced by retroviral vectors, Science, 243, 220, 1989.
90. Zwiebel, J. A. et al., Recombinant gene expression in human umbilical vein endothelial cells transduced by retroviral vectors, Biochem. Biophys. Res. Comm., 170, 209, 1990.
91. Conte, M. S. et al., Endothelial cell seeding fails to attenuate intimal thickening in balloon-injured rabbit arteries, J. Vasc. Surg., 21, 413, 1995.
92. Edelstein, S. B. and Breakefield, X. O., Human fibroblast cultures, in Physico-Chemical Methodoligies in Psychiatric Research, Hanin, I. and Koslow, S., Eds., Raven Press, New York, 1980, 199.
93. Déglon, N. et al., Central nervous system delivery of recombinant ciliary neurotrophic factor by polymer encapsulated differentiated C2C12 myoblasts, Hum. Gene Ther., 7, 2135, 1996.
94. Sah, D. W. Y., Ray, J., and Gage, F. H., Bipotent progenitor cell lines from the human CNS, Nat. Biotech., 15, 574, 1997.
95. Snyder, E. Y. et al., Multipotent neural cell lines can engraft and participate in development of mouse cerebellum, Cell, 68, 33, 1992.
96. Snyder, E. Y., Grafting immortalized neurons to the CNS, Curr. Opin. Neurobiol., 4, 742, 1994.
97. Snyder, E. Y. and Macklis, J. D., Multipotent neural progenitor or stem-like cells may be uniquely suited for therapy for some neurodegenerative conditions, Clin. Neurosci., 3, 310, 1995.
98. Lampson, L. A., Molecular bases of the immune response to neural antigens, Trends Neurosci., 10, 211, 1987.
99. Frim, D. M. et al., Implanted fibroblasts genetically engineered to produce brainderived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat, Proc. Natl. Acad. Sci. USA, 91, 5104, 1994.
100. Louis, J.C. et al., CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death, Science, 259, 689, 1993.
101. Snyder, E. Y., Neural stem-like cells: Developmental lessons with therapeutic potential, Neuroscientist, 4, 408, 1998.
102. Wolfe, J. H., Deshmane, S. L., and Fraser, N. W., Herpesvirus vector gene transfer and expression of beta-glucuronidase in the central nervous system of MPS VII mice, Nat. Genet., 1, 379, 1992.
103. Hoffman, D. et al., Transplantation of a polymer encapsulated cell line genetically engineered to release NGF, Exptl. Neurol., 122, 100, 1993.
104. Sagot, Y. et al., Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse, Eur. J. Neurosci., 7, 1313, 1995.
105. Ram, Z. et al., In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats, Cancer Res., 53, 83, 1993.
106. Sena-Esteves, M. et al., Single step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein Barr virus hybrid amplicons, J. Virol., 73, 10426, 1999.
107. Harvey, A. R. et al., Survival and migration of transplanted male glia in adult female mouse brains monitored by a Y-chromosome-specific probe, Mol. Brain Res., 12, 339, 1992.
108. Bhide, P. G., Cell cycle kinetics in the embryonic mouse corpus striatum, J. Comp. Neurol., 374, 506, 1996.
109. Schwartz, M. L., Rakic, P., and Goldman-Rakic, P. S., Early phenotype expression of cortical neurons: Evidence that a subclass of migrating neurons have callosal axons, Proc. Natl. Acad. Sci. USA, 88, 1354, 1991.
110. Lewin, M. et al., Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells, Nat. Biotechnol., 18, 410, 2000.
111. Bulte, J. W. et al., Neurotransplantation of magnetically labeled oligodendrocyte progenitors:Magnetic resonance tracking of cell migration and myelination, Proc. Natl. Acad. Sci. USA, 96, 15256, 1999.
112. Schellingerhout, D. et al., Mapping the in vivo distribution of herpes symplex virons, Hum. Gene Ther., 20, 1543, 1998.
113. Tsien, R. Y., The green fluorescent protein, Annu. Rev. Biochem., 67, 509, 1998.
114. Aboody-Guterman, K. et al., Green fluorescent protein as a reporter for retrovirus and helper virus-free HSV-1 amplicon vector-mediated gene transfer into neural cells in culture and in vivo, NeuroReport, 8, 3801, 1997.
115. Hoffman, R. M., Orthotopic transplant mouse models with green fluorescent proteinexpressing cancer cells to visualize metastasis and angiogeneisis, Cancer Meta. Rev., 17, 271, 1999.
116. Potter, S. M. et al., Intravital imaging of green fluorescent protein using two-photon laser-scanning microscopy, Gene, 173, 25, 1996.
117. Weissleder, R. et al., In vivo magnetic resonance imaging of transgene expression, Nat. Med., 6, 351, 2000.
118. Wood, K. V., Marker proteins for gene expression, Curr. Opin. Biotechnol., 6, 50, 1995.
119. Contag, P. R. et al., Bioluminescent indicators in living mammals, Nat. Med., 4, 245, 1998.
120. Weissleder, R. et al., In vivo imaging of tumors with protease-activated near-infrared fluorescent probes, Nat. Biotech., 17, 375, 1999.
121. MacLaren, D. C. et al., Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals, Gene Ther., 6, 785, 1999.
122. Zlokovic, B. V. and Apuzzo, M. L., Cellular and molecular neurosurgery: Pathways from concept to reality - Part II: Vector systems and delivery methodologies for gene therapy of the central nervous system, Neurosurgery, 40, 805, 1997.
123. Rainov, N. G., Breakefield, X. O., and Kramm, C. M., Routes of vector application for brain tumor gene therapy, Gene Ther. Mol. Biol., 3, 1, 1999.
124. Badie, B. et al., Stereotactic delivery of a recombinant adenovirus into a C6 glioma cell line in a rat brain tumor model, Neurosurgery, 35, 910, 1994.
125. Boviatsis, E. J. et al., Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors, Hum. Gene Ther., 5, 183, 1994.
126. Chen, S. H. et al., Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo, Proc. Natl. Acad. Sci. USA, 91, 3054, 1994.
127. Eck, S. L. et al., Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: A phase I trial, Hum. Gene Ther., 7, 1465, 1996.
128. Le Gal La Salle, G. et al., An adenovirus vector for gene transfer into neurons and glia in the brain, Science, 259, 988, 1993.
129. Morsy, M. A. et al., An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene, Proc. Natl. Acad. Sci. USA, 95, 7866, 1998.
130. Caillaud, C. et al., Adenoviral vector as a gene delivery system into cultured rat neuronal and glial cells, Eur. J. Neurosci., 5, 1287, 1993.
131. Puumalainen, A. M. et al., Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses, Hum. Gene Ther., 9, 1769, 1998.
132. Viola, J. J. et al., Adenovirally mediated gene transfer into experimental solid brain tumors and leptomeningial cancer cells, J. Neurosurg., 82, 70, 1995.
133. Bartlett, J. S., Samulski, R. J., and McCown, T. J., Selective and rapid uptake of adeno-associated virus type 2 in brain, Hum. Gene Ther., 9, 1181, 1998.
134. Lo, W. D. et al., Adeno-associated virus-mediated gene transfer to the brain: Duration and modulation of expression, Hum. Gene Ther., 10, 201, 1999.
135. Mizuno, M. et al., Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration, Jpn. J. Cancer Res., 89, 76, 1998.
136. Okada, H. et al., Gene therapy against an experimental glioma using adeno-associated virus vectors, Gene Ther., 3, 957, 1996.
137. Wu, P. et al., Adeno-associated virus vector-mediated transgene integration into neurons and other nondividing cell targets, J. Virol., 72, 5919, 1998.
138. Chiocca, E. A. et al., Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants, New Biol., 2, 739, 1990.
139. Chambers, R. et al., Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma, Proc. Natl. Acad. Sci. USA, 92, 1411, 1995.
140. Kaplitt, M. G. et al., Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain, Nat. Genet., 8, 148, 1994.
141. Mineta, T., Rabkin, S. D., and Martuza, R. L., Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant, Cancer Res., 54, 3963, 1994.
142. Blömer, U. et al., Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector, J. Virol., 71, 6641, 1997.
143. Galipeau, J. et al., Vesicular stomatitis virus G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer, Cancer Res., 59, 2384, 1999.
144. Naldini, L. et al., Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector, Proc. Natl. Acad. Sci. USA, 93, 11382, 1996.
145. Price, J., Turner, D., and Cepko, C., Lineage analysis in the vertebrate nervous system by retrovirusmediated gene transfer, Proc. Natl. Acad. Sci. USA, 84, 156, 1987.
146. Yagi, K. et al., Interferon-beta endogenously produced by intratumoral injection of cationic liposome-encapsulated gene: Cytocidal effect on glioma transplanted into nude mouse brain, Biochem. Mol. Biol. Int., 32, 167, 1994.
147. Zerrouqi, A. et al., Liposomal delivery of the herpes simplex virus thymidine kinase gene in glioma: Improvement of cell sensitization to ganciclovir, Cancer Gene Ther., 3, 385, 1996.
148. Zhu, J. et al., A continuous intracerebral gene delivery system for in vivo liposomemediated gene therapy, Gene Ther., 3, 472, 1996.
149. Bensadoun, J. C. et al., Lentiviral vectors as a gene delivery system in the mouse midbrain: Cellular and behavioral improvements in a 6-OHDA model of Parkinson’s disease using GDNF, Exp. Neurol., 164, 15, 2000.
150. During, M. J. et al., Long-term behavioral recovery in Parkinsonian rats by an HSV vector expressing tyrosine hydroxylase, Science, 266, 13990, 1994.
151. Leff, S. E. et al., Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson’s disease, Neuroscience, 92, 185, 1999.
152. Lundberg, C. et al., Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: In vitro characterization and in vivo effects in the rat Parkinson model, Exp. Neurol., 139, 39, 1996.
153. Schumacher, J. M. et al., Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids, Neuroscience, 45, 561, 1991.
154. Kordower, J. H. et al., Grafts of EGF-responsive neural stem cells derived from GFAP-hNGF transgenic mice: Trophic and tropic effects in a rodent model of Huntington’s disease, J. Comp. Neurol., 387, 96, 1997.
155. Geddes, B. J. et al., Long-term gene therapy in the CNS: Reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin, Nat. Med., 3, 1402, 1997.
156. Jain, R. K., Transport of molecules in the tumor interstitium: A review, Cancer Res., 47, 3039, 1987.
157. Rainov, N. G. et al., Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm, Cancer Gene Ther., 3, 99, 1996.
158. Raffel, C. et al., Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system, Hum. Gene Ther., 5, 863, 1994.
159. Ram, Z. et al., Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells, Nat. Med., 3, 1354, 1997.
160. Bobo, R. H. et al., Convection-enhanced delivery of macromolecules in the brain, Proc. Natl. Acad. Sci. USA, 91, 2076, 1994.
161. Morrison, P. F. et al., Focal delivery during direct infusion to brain: Role of flow rate, catheter diameter, and tissue mechanics, Am. J. Physiol., 277, 1218, 1999.
162. Bankiewicz, K. S. et al., Convection-enhanced delivery of AAV vector in Parkinsonian monkeys: In vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach, Exp. Neurol., 164, 2, 2000.
163. Bischoff, J. R. et al., An adenovirus mutant that replicates selectively in p53-deficient human tumor cells, Science, 274, 373, 1996.
164. Yazaki, T. et al., Treatment of human malignant meningiomas by G207, a replicationcompetent multimutated herpes simplex virus 1, Cancer Res., 55, 4752, 1995.
165. Harsh, G. R. et al., Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: A gene-marking and neuropathologic study, J. Neurosurg., 92, 804, 2000.
166. Franklin, K. B. J. and Paxinos, G., The Mouse Brain in Stereotaxic Coordinates, Academic Press, New York, 1997.
167. Paxinos, G. and Watson, C., The Rat Brain in Stereotaxic Coordinates, 4th ed., Academic Press, New York, 1998.
168. Chen, M. Y. et al., Variables affecting convection-enhanced delivery to the striatum:A systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time, J. Neurosurg., 90, 315, 1999.
169. Kaufman, M. H., The Atlas of Mouse Development, Academic Press, New York, 1992.
170. Paxinos, G. et al., Atlas of the Developing Rat Nervous System, 2nd ed., Academic Press, New York, 1994.
171. Turkay, A., Saunders, T., and Kurachi, K., Intrauterine gene transfer: Gestational stage-specific gene delivery in mice, Gene Ther., 6, 1685, 1990.
172. Messina, L. M. et al., Adhesion and incorporation of lacZ-transduced endothelial cells into the intact capillary wall in the rat, Proc. Natl. Acad. Sci. USA, 89, 12018, 1992.
173. Vane, J. R., Anggard, E. E., and Botting, R. M., Regulatory functions of the vascular endothelium, N. Engl. J. Med., 323, 27, 1990.
174. Ward, P. A., Mechanisms of endothelial cell injury, J. Lab. Clin. Med., 118, 421, 1991.
175. Pober, J. S., Cytokine-mediated activation of vascular endothelium. Physiology and pathology, Am. J. Path., 133, 426, 1988.
176. Belloni, P. N. and Tressler, R. J., Microvascular endothelial cell heterogeneity: Interactions with leukocytes and tumor cells, Cancer Mesta. Rev., 8, 353, 1990.
177. Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other diseases, Nat. Med., 1, 27, 1995.
178. Folkman, J., Addressing tumor blood vessels, Nat. Biotech, 15, 510, 1997.
179. Risau, W. and Flamme, I., Vasculogenesis, Annu. Rev. Cell. Biol., 11, 73, 1995.
180. Hanahan, D. and Folkman, J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell, 86, 353, 1996.
181. Brooks, P. C. et al., Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels, Cell, 79, 1157, 1994.
182. Hammes, H. P. et al., Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization, Nat. Med., 2, 529, 1996.
183. Martini-Baron, G. and Marme, D., VEGF-mediated tumor angiogenesis: A new target for cancer therapy, Curr. Opin. Biotech., 6, 675, 1995.
184. Hanahan, D., Signaling vascular morphogenesis and maintenance, Science, 277, 48, 1997.
185. Risau, W., Mechanisms of angiogenesis, Nature, 386, 671, 1997.
186. Deneckamp, J. Endothelial cell proliferation is a novel approach to targeting tumor therapy, Br. J. Cancer, 45, 136, 1982.
187. Fidler, I. J. and Hart, I. R., Biological diversity in metastatic neoplasms: Origins and implications, Science, 217, 998-1003, 1982.
188. Johnson, R. C. et al., Endothelial cell membrane vesicles in the study of organ preferences of metastasis, Cancer Res., 51, 394, 1991.
189. Springer, T. A., Traffic signals for lymphocyte circulation and leukocyte emigration:The multistep paradigm, Cell, 76, 301, 1994.
190. Salmi, M. et al., Selective endothelial binding of interleukin-2-dependent human Tcell derived from different tissues, Proc. Natl. Acad. Sci. USA, 89, 11436, 1992.
191. Rosen, S. D. and Bertozzi, C. R., The selectins and their ligands, Curr. Opin. Cell Biol., 6, 663, 1994.
192. Bevilacqua, M. P. et al., Endothelial leukocyte adhesion molecule1: An inducible receptor for neutrophils related to complement regulatory proteins and lectins, Science, 243, 1160, 1989.
193. Siegelman, M. H., Rijn, M., and Weissman, I. L., Mouse lymph node hominy receptor cDNA clone encodes a glycoprotein revealing tandem interaction domains, Science, 243, 1165, 1989.
194. Cepek, K. L. et al., Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin, Nature, 372, 190, 1994.
195. Johnson, R. C. et al., Lung endothelial dipeptidyl peptidase IV is an adhesion molecular for lung-metastatic rat breast and prostate carcinoma cells, J. Cell Biol., 121, 1423, 1993.
196. Bresolin, N. et al., Intra-aortic injection of myoblasts in mdx mice: Genetic and technitium-99 m cell labeling and biodistribution, Muscle Nerve, 20, 757, 1997.
197. Neumayer, A. M., Di Gregoio, D. M., and Brown, R. H., Arterial delivery of myoblasts to skeletal muscle, Neurology, 42, 2258, 1992.
198. Gupta, S. et al., Entry and integration of transplanted hepatocytes in rat liver plates occur by disruption of hepatic sinusoidal endothelium, Hepatology, 29, 509, 1999.
199. Cliff, W. J., Observations on healing tissue: A combined light and electron microscopic investigation, Philos. Trans. R. Soc. (London), 246, 305, 1963.
200. Rhodin, J. A. G. and Fujita, H., Capillary growth in the mesentery of young normal rats. Intravital video and electron microscope analyses, J. Submicrose Cytol. Pathol., 21, 1, 1989.
201. Nehls, V., Denzer, K., and Drenckhahn, D., Pericyte involvement in capillary sprouting during angiogenesis in situ, Cell Tissue Res., 270, 469, 1992.
202. Kon, K. and Fujiwara, T., Transformation of fibroblasts into endothelial cells during angiogenesis, Cell Tissue Res., 278, 625, 1994.
203. Aloisi, M., Giacomin, C., and Tessari, R., Growth of elementary blood vessels in diffusion chambers. I. Process of formation and conditioning factors, Virchows Arch. B Cell. Pathol., 6, 350, 1970.
204. Hammersen, F., Endrich, B., and Messmer, K., The fine structure of tumor blood vessels. I. Participation of non-endothelial cells in tumor angiogenesis, Int. J. Microcirc. Clin. Exp, 4, 31, 1985.
205. Overturf, K. et al., Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinemia type I, Nat. Genet., 12, 266, 1996.
206. Johnston, P. et al., Delivery of human fibroblast growth factor-1 gene to brain by modified rat brain endothelial cells, J. Neurochem., 67, 1643, 1996.
207. Nabel, E. G. et al., Recombinant gene expression in vivo within endothelial cells of the arterial wall, Science, 244, 1342, 1989.
208. Ojeifo, J. O. et al., Angiogenesis-directed implantation of genetically modified endothelial cells in mice, Cancer Res., 55, 2240, 1995.
209. Brown, A.B. et al., Vascular targeting of therapeutic cells to tumors, submitted.
210. Arbiser, J. L. et al., Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways, Proc. Natl. Acad. Sci. USA, 94, 861, 1997.
211. Spear, M. A. et al., Targeting gene therapy vectors for CNS malignancies, J. Neurovirol., 4, 133, 1998.
212. Muldoon, L. L. et al., Delivery of therapeutic genes to brain and intracerebral tumors, in Gene Therapy for Neurological Disorders and Brain Tumors, Chiocca, E. A. and Breakefield, X. O., Eds., Humana Press, Totowa, NJ, 1997, 128.
213. Cox, D. J., Pilkington, G. J., and Lantos, P. L., The fine structure of blood vessels in ethylnitrosurea-induced tumours of the rat nervous system: With special reference to the breakdown of the blood-brain-barrier, Br. J. Exp. Pathol., 57, 419, 1976.
214. Yamada, K. et al., Quantitative autoradiographic measurements of blood-brain barrier permeability in the rat glioma model, J. Neurosurg., 57, 394, 1982.
215. Groothuis, D. R. et al., Quantitative measurements of capillary transport in human brain tumors by computed tomography, Ann. Neurol., 30, 581, 1991.
216. Jain, R. K., Barriers to drug delivery in solid tumors, Sci. Am., 271, 58, 1994.
217. Chauvet, A. E. et al., Selective intraarterial gene delivery into a canine meningioma, J. Neurosurg., 88, 870, 1998.
218. Rainov, N. G. et al., Intra-arterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms, Hum. Gene Ther., 10, 311, 1999.
219. Neuwelt, E. A., Pagel, M. A., and Dix, R. D., Delivery of ultraviolet inactivated 35Sherpesvirus across an osmotically modified blood-brain barrier, J. Neurosurg., 74, 475, 1991.
220. Schellingerhout, D. et al., Quantitation of HSV mass distribution in a rodent brain tumor model, Gene Ther., 7, 1648, 2000.
221. Doran, S. E. et al., Gene expression from recombinant viral vectors in the CNS following blood-brain barrier disruption, Neurosurgery, 36, 965, 1995.
222. Neuwelt, E. A. and Hill, S. A., Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases, J. Neuro-Oncol., 4, 195, 1987.
223. Zünkeler, B. et al., Quantification and pharmacokinetics of blood-brain barrier disruption in humans, J. Neurosurg., 85, 1056, 1996.
224. Rapoport, S. I. and Robinson, P. J., Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier, Ann. NY Acad. Sci, 481, 250, 1986.
225. Black, K. L. and Chio, C. C., Increased opening of blood-tumor barrier by leukotriene C4 is dependent on size of molecules, Neurol. Res., 14, 402, 1992.
226. Chio, C. C., Baba, T., and Black, K. L., Selective blood-tumor barrier disruption by leukotrienes, J. Neurosurg., 77, 407, 1992.
227. Black, K. L. et al., Intracarotid infusion of RMP-7, a bradykinin analog and transport of gallium-68 ethylenediamine tetra-acetic acid into human gliomas, J. Neurosurg., 86, 603, 1997.
228. Doctrow, S. R. et al., The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvascular endothelial cells, J. Pharmacol. Exp. Ther., 271, 229, 1994.
229. Elliott, P. J. et al., Unlocking the blood-brain barrier: A role for RMP-7 in brain tumor therapy, Exp. Neurol., 141, 214, 1996.
230. Inamura, T. et al., Intracarotid histamine infusion increases blood tumor permeability in RG2 glioma, Neurol. Res., 16, 125, 1994.
231. Matsukado, K. et al., Selective increase in blood-tumor barrier permeability by calcium antagonists in transplanted rat brain tumors, Acta Neurochir., 60, 403, 1994.
232. Nakano, S., Matsukado, K., and Black, K. L., Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide, Cancer Res., 56, 4027, 1996.
233. Nomura, T. et al., Effect of histamine on the blood-tumor barrier in transplanted rat brain tumors, Acta Neurochir., 60, 400, 1994.
234. Hess, J. F. et al., Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor, Biochem. Biophys. Res. Comm., 184, 260, 1992.
235. Sanovich, E. et al., Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7, Brain Res., 705, 125, 1995.
236. Raymond, J. J., Robertson, D. M., and Dinsdale, H. B., Pharmacological modification of bradykinin induced breakdown of the blood-brain barrier, Can. J. Neurol. Sci., 13, 214, 1986.
237. Willson, J. K., A new technique for cerebral angiography: The variable stiffness guidewire, Radiology, 134, 427, 1980.
238. Driesse, M. J. et al., Distribution of recombinant adenovirus in the cerebrospinal fluid of nonhuman primates, Hum. Gene Ther., 10, 2347, 1999.
239. Kramm, C. M. et al., Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors, Hum. Gene Ther., 7, 291, 1996.
240. Elliger, S.S. et al., Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector, Gene Ther., 6, 1175, 1999.
241. Ghodsi, A. et al., Extensive beta-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain, Hum. Gene Ther., 9, 2340, 1998.
242. Ohashi, T. et al., Adenovirus-mediated gene transfer and expression of human betaglucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice, Proc. Natl. Acad. Sci. USA, 94, 1287, 1997.
243. Sferra, T. J. et al., Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse, Hum. Gene Ther., 11, 507, 2000.
244. Ram, Z. et al., Intrathecal gene therapy for malignant leptomeningial neoplasia, Cancer Res., 54, 2141, 1994.
245. Oshiro, E. M. et al., Toxicity studies and distribution dynamics of retroviral vectors following intrathecal administration of retroviral vector-producer cells, Cancer Gene Ther., 2, 87, 1995.
246. Bajocchi, G. et al., Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors, Nat. Genet., 3, 229, 1993.
247. Ooboshi, H. et al., Adenovirus-mediated gene transfer in vivo to cerebral blood vessels and perivascular tissue, Circ. Res., 77, 7, 1995.
248. Ooboshi, H., Rios, C. D., and Heistad, D. D., Novel methods for adenovirus-mediated gene transfer to blood vessels in vivo, Mol. Cell Biochem., 172, 37, 1997.
249. Vincent, A. J. et al., Treatment of leptomeningial metastases in a rat model using a recombinant adenovirus containing the HSV-tk gene, J. Neurosurg., 85, 648, 1996.
250. Rosenfeld, M. R. et al., Adeno-associated viral vector gene transfer into leptomeningial xenografts, J. Neuro-Oncol., 34, 139, 1997.
251. Lam, P. Y. P. and Breakefield, X. O., Hybrid vector designs to control the delivery, fate and expression of transgenes, J. Gene Med., 2, 395, 2000.
252. Schwartz, M. L. et al., Brain-specific enhancement of the mouse neurofilament heavy gene promoter in vitro, J. Biol. Chem., 269, 13444, 1994.
253. Charron, G. et al., Multiple neuron-specific enhancers in the gene coding for the human neurofilament light chain, J. Biol. Chem., 270, 30604, 1995.
254. Forss-Petter, S. et al., Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control, Neuron, 5, 187, 1990.
255. Lemaire-Vieille, C. et al., Epithelial and endothelial expression of the green fluorescent protein reporter gene under the control of bovine prion protein (PrP) gene regulatory sequences in transgenic mice, Proc. Natl. Acad. Sci. USA, 97, 5422, 2000.
256. Auerbach, S. D. et al., Human amiloride-sensitive epithelial NA+ channel gamma subunit promoter: Functional analysis and identification of a polypurine-polypyrimidine tract with the potential for triplex DNA formation, Biochem. J., 347, 105, 2000.
257. Maue, R. A. et al., Neuron-specific expression of the rat brain type II sodium channel gene is directed by upstream regulatory elements, Neuron, 4, 223, 1990.
258. Schimmell, J. J. et al., 4.5 kb of the rat tyrosine hydroxylase 5′ flanking sequence directs tissue specific expression during development and contains consensus sites for multiple transcription factors, Mol. Brain Res., 74, 1, 1999.
259. Chan, R. M., Stewart, M. J., and Crabb, D. W., A direct repeat (DR-1) element in the first exon modulates transcription of the preproenkephalin A gene, Mol. Brain Res., 45, 50, 1997.
260. McDonough, J. et al., Regulation of transcription in the neuronal nicotinic receptor subunit gene cluster by a neuron-selective enhancer and ETS domain factors, J. Biol. Chem., 2000.
261. Naciff, J. M. et al., Identification and transgenic analysis of a murine promoter that targets cholinergic neuron expression, J. Neurochem., 72, 17, 1999.
262. McLean, P. J. et al., A minimal promoter for the GABA(A) receptor alpha6-subunit gene controls tissue specificity, J. Neurochem., 74, 1858, 2000.
263. Klein, M. et al., Cloning and characterization of promoter and 5′-UTR of the NMDA receptor subunit epsilon 2: Evidence for alternative splicing of 5′-non-coding exon, Gene, 208, 259, 1998.
264. Adam M. A. et al., Internal initiation of translation in retroviral vectors carrying picornavirus 5′ nontranslated regions, J. Virol., 65, 4985-4990, 1991.
265. Miyao, Y. et al., Selective expression of foreign genes in glioma cells: Use of the mouse myelin basic protein gene promoter to direct toxic gene expression, J. Neurosci. Res., 36, 472, 1993.
266. Mavria, G., Jager, U., and Porter, C. D., Generation of a high titre retroviral vector for endothelial cell-specific gene expression in vivo, Gene Ther., 7, 368, 2000.
267. Kurihara, H. et al., Glioma/glioblastoma-specific adenoviral gene expression using the nestin gene regulator, Gene Ther., 7, 686, 2000.
268. Fraefel, C. et al., Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells, J. Virol., 70, 7190, 1996.